NCT01856803View on ClinicalTrials.gov

Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2019

Conditions
Leukemia, GVHD, ATG, Transplantation
Interventions
DRUG

anti thymoglobulin

Trial Locations (1)

100044

Peking university people's hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT01856803 - Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis | Biotech Hunter | Biotech Hunter